Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at

View all releases Recent Press Releases

Nov 24, 2015 Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled
Nov 12, 2015 Regeneron Celebrates Patient Innovation and Growth in New York State
Nov 10, 2015 Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015
Nov 8, 2015 Regeneron and Sanofi Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
Nov 5, 2015 New Survey of U.S. Adults with Diabetes Reveals Less than Half Understand Their Risk for Vision Loss
Nov 5, 2015 Regeneron and Sanofi to Present Results from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2015
Nov 4, 2015 Regeneron Reports Third Quarter 2015 Financial and Operating Results
Oct 30, 2015 Regeneron Announces EU Approval of EYLEA® (aflibercept) Injection for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization
Oct 29, 2015 Regeneron Named Among Top Two Global Biopharmaceutical Employers by Science Magazine for Fifth Year in a Row
Oct 23, 2015 Regeneron Announces Presentation at the 24th Annual Credit Suisse Healthcare Conference

Form content here please :)